Atara Biotherapeutics Inc. Common Stock (ATRA)
Stock · NASDAQ · Health Care
$9.18as of 10/16/2026
Price chart
Active signals
ATRA Signal Track Record
How signals performed across all stocks →What ATRA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -2.9% | 43% | October 1, 2026 |
| Bollinger Band Breakout | 23 | -7.1% | 30% | August 12, 2026 |
| Bollinger Band Breakdown | 17 | +9.3% | 59% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -12.8% | 38% | September 24, 2026 |
| Any 20-session window (baseline) | -0.3% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ATRA
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseas…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 10
- Website
- www.atarabio.com/
Fundamentals
- 1-day range
- $9.25$9.58
- Market cap
- $74.33M
- P/E (trailing)
- —
- P/E (forward)
- 6.10
- EPS (trailing)
- $-1.18
- Dividend yield
- —
- Beta
- 0.33
- Avg. volume
- 53.1K
How Atara Biotherapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 16, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Atara Biotherapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ATRAAtara Biotherapeutics Inc. Common Stock$9.18▼ 4.87%Market cap $74.33MP/E —$3.92$19.15
- CRDFCardiff Oncology Inc. Common Stock$0.9▼ 7.22%Market cap $74.71MP/E —$0.7566$3.31
- LONALeonaBio Inc. Common Stock$5.2▼ 1.70%Market cap $73.36MP/E —$2.21$14.21
- CSBRChampions Oncology Inc. Common Stock$4.7▼ 1.88%Market cap $72.11MP/E —$4.59$8.31
- ELOXEloxx Pharmaceuticals Inc. Common Stock$13.03▼ 4.89%Market cap $71.48MP/E —$0$23.4
- IMAImageneBio Inc. Common Stock$4.04▲ 0.25%Market cap $63.50MP/E —$3.9$9.1
- GNTAGenenta Science S.p.A. American Depositary Shares$0.675▲ 0.90%Market cap $63.16MP/E —$0.55$10
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ATRA Atara Biotherapeutics Inc. Common Stock | $74.33M | — | $9.18 | ▼ 4.87% | $3.92$19.15 |
| CRDF Cardiff Oncology Inc. Common Stock | $74.71M | — | $0.9 | ▼ 7.22% | $0.7566$3.31 |
| LONA LeonaBio Inc. Common Stock | $73.36M | — | $5.2 | ▼ 1.70% | $2.21$14.21 |
| CSBR Champions Oncology Inc. Common Stock | $72.11M | — | $4.7 | ▼ 1.88% | $4.59$8.31 |
| ELOX Eloxx Pharmaceuticals Inc. Common Stock | $71.48M | — | $13.03 | ▼ 4.89% | $0$23.4 |
| IMA ImageneBio Inc. Common Stock | $63.50M | — | $4.04 | ▲ 0.25% | $3.9$9.1 |
| GNTA Genenta Science S.p.A. American Depositary Shares | $63.16M | — | $0.675 | ▲ 0.90% | $0.55$10 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug AdministrationYahoo · 9/30/2026
- Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Partner Refiles Tabelecleucel Biologics License Application With FDABenzinga · 9/30/2026
- HQL: The Rally That Makes Growth Harder (Rating Downgrade)SeekingAlpha · 9/15/2026
Insider Activity
Insider Actions →- Brian N. Cherry · September 4, 2026 · Buy104.2K @ $9.6
- AnhCo Nguyen · August 17, 2026 · Sale5.1K @ $8.08
- Redmile Group, LLC · July 22, 2026 · Tax Withholding60
- Redmile Group, LLC · July 22, 2026 · Option Exercise55.4K
- Redmile Group, LLC · July 22, 2026 · Option Exercise38.7K
- Redmile Group, LLC · July 22, 2026 · Option Exercise101.1K
- Redmile Group, LLC · July 22, 2026 · Option Exercise195.2K
- Brian N. Cherry · June 11, 2026 · Grant24.0K
- Gregory Austin Ciongoli · June 9, 2026 · Grant12.0K
- Matthew K. Fust · June 9, 2026 · Grant12.0K
- William K. Heiden · June 9, 2026 · Grant12.0K
- AnhCo Nguyen · May 18, 2026 · Sale5.2K @ $9.13
- Yanina Grant-Huerta · May 18, 2026 · Sale2.4K @ $9.13
- EcoR1 Capital, LLC · May 7, 2026 · Buy507.4K @ $9.35
- James Huang · May 7, 2026 · Sale313.4K @ $10.1
Institutional Ownership
March 31, 2026
- Total shares held
- 2.53M
- Total value held
- $11.34M
- Institutional holders
- 31
- Unknown700.0K
- Unknown441.7K
- Unknown313.6K
- Unknown217.9K
- Unknown194.3K
- Unknown130.9K
- Unknown99.6K
- Unknown79.0K
- Unknown66.1K
- Unknown50.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA
Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA. Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.